MDGL MADRIGAL PHARMACEUTICALS INC Product Launches 8-K Filing 2023 - FDA Submission Madrigal Pharmaceuticals completed its submission of a New Drug Application for resmetirom to the FDA for the treatment of NASH with liver fibrosis.Get access to all SEC 8-K filings of the MADRIGAL PHARMACEUTICALS INC